These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24310424)

  • 21. Total allowable concentrations of monomeric inorganic aluminum and hydrated aluminum silicates in drinking water.
    Willhite CC; Ball GL; McLellan CJ
    Crit Rev Toxicol; 2012 May; 42(5):358-442. PubMed ID: 22512666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.
    Pratt RD; Swinkels DW; Ikizler TA; Gupta A
    J Clin Pharmacol; 2017 Mar; 57(3):312-320. PubMed ID: 27557937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
    Gelone DK; Park JM; Lake KD
    Pharmacotherapy; 2007 Sep; 27(9):1272-8. PubMed ID: 17723081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effectiveness and tolerability of oral liquid ferrous gluconate in iron-deficiency anemia in pregnancy and in the immediate post-partum period: comparison with other liquid or solid formulations containing bivalent or trivalent iron].
    Casparis D; Del Carlo P; Branconi F; Grossi A; Merante D; Gafforio L
    Minerva Ginecol; 1996 Nov; 48(11):511-8. PubMed ID: 9005381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography.
    Beshara S; Lundqvist H; Sundin J; Lubberink M; Tolmachev V; Valind S; Antoni G; Långström B; Danielson BG
    Br J Haematol; 1999 Feb; 104(2):296-302. PubMed ID: 10050711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations for optimal iron use for anemia due to chronic kidney disease.
    Hudson JQ; Comstock TJ
    Clin Ther; 2001 Oct; 23(10):1637-71. PubMed ID: 11726002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro studies on interactions of iron salts and complexes with food-stuffs and medicaments.
    Geisser P
    Arzneimittelforschung; 1990 Jul; 40(7):754-60. PubMed ID: 2222551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Vaziri ND; Kalantar-Zadeh K; Wish JB
    Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron Pharmacokinetics in Women with Iron Deficiency Anaemia Following A Single Oral Dose of a Novel Formulation of Tardyferon (Prolonged Release Ferrous Sulphate).
    Leary A; Barthe L; Clavel T; Sanchez C; Issiakhem Z; Paillard B; Edmond JM
    Drug Res (Stuttg); 2017 Nov; 67(11):647-652. PubMed ID: 28724166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
    Balakrishnan VS; Rao M; Kausz AT; Brenner L; Pereira BJ; Frigo TB; Lewis JM
    Eur J Clin Invest; 2009 Jun; 39(6):489-96. PubMed ID: 19397688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography.
    Beshara S; Sörensen J; Lubberink M; Tolmachev V; Långström B; Antoni G; Danielson BG; Lundqvist H
    Br J Haematol; 2003 Mar; 120(5):853-9. PubMed ID: 12614222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
    Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
    Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Review by expert group in the diagnosis and treatment of anemia in pregnant women. Federación Mexicana de Colegios de Obstetricia y Ginecología].
    Montoya Romero Jde J; Castelazo Morales E; Valerio Castro E; Velázquez Cornejo G; Nava Muñoz DA; Escárcega Preciado JA; Montoya Cossío J; Pichardo Villalón GM; Maldonado Aragón A; Santana García HR; Fajardo Dueñas S; Mondragón Galindo CG; García Lee T; García A; Hernández de Morán M; Chávez Güitrón LE; Jiménez Gutiérrez C;
    Ginecol Obstet Mex; 2012 Sep; 80(9):563-80. PubMed ID: 23243836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
    Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
    Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis.
    Cazzola M; Ponchio L; de Benedetti F; Ravelli A; Rosti V; Beguin Y; Invernizzi R; Barosi G; Martini A
    Blood; 1996 Jun; 87(11):4824-30. PubMed ID: 8639855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.